



**PARTICIPANT STATISTICS**

**HEPATITIS MARKERS**

**FIRST QUADRIMESTER 2011**

**anti-HCV**

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
Abbott AxSYM	12			12			11		1	12			1		11
Adaltis EIAgen HCV	3			3			3			3					3
J&J Vitros	8			8			8			8					8
Ortho HCV Version 3.0 ELISA	16			16			16			16					16
Siemens Advia	10			10			10			10					9
Abbott Architect	4			4			4			4			1		3
Roche Elecsys	3			3			2		1	3					3
<b>Total Population</b>	<b>61</b>	<b>0</b>	<b>0</b>	<b>61</b>	<b>0</b>	<b>0</b>	<b>59</b>		<b>2</b>	<b>61</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>58</b>
<b>Flagging</b>	*****	*****		*****	*****		*****	*****		*****	*****	*****	*****	*****	*****

**anti-HBc IgG + IgM**

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
Abbott AxSYM Core			8			8			8			8			8
Bio-Rad MONOLISA EIA			4			4			4			4			4
DiaSorin ETI-AB-COREK/Plus			5			5			5			5			5
J&J Vitros			5			5			5			5			5
Siemens Advia			8			8			8			8			8
Siemens Immulite 2000			7			7			7			7			7
<b>Total Population</b>	<b>0</b>	<b>0</b>	<b>41</b>	<b>0</b>	<b>0</b>	<b>41</b>	<b>41</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>41</b>	<b>41</b>	<b>0</b>	<b>0</b>
<b>Flagging</b>	*****	*****		*****	*****		*****	*****	*****	*****	*****	*****	*****	*****	*****

**anti-HBc IgM**

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
Abbott Core-M	3		1	4			4			3		1	4		
Bio-Rad MONOLISA EIA			2	2			2					2	2		
DiaSorin ETI-CORE-IGMK Plus	1		3	4			4			1		3	4		
J&J Vitros	3			3			3			3			3		
Siemens Advia			3			3			3			3	3		
Siemens Immulite	4		2	5		1	6			4		2	6		
<b>Total Population</b>	<b>12</b>	<b>0</b>	<b>14</b>	<b>20</b>	<b>0</b>	<b>6</b>	<b>26</b>	<b>0</b>	<b>0</b>	<b>11</b>	<b>1</b>	<b>14</b>	<b>26</b>	<b>0</b>	<b>0</b>
<b>Flagging</b>					*****	*****		*****	*****					*****	*****

Due to a lack of participant consensus specimens 1 and 4 were not evaluated this event.

**anti-HBs**

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
Abbott Architect	2					2			2	1			1	2	
Abbott Ausab EIA Proc A	2					2			2	2			2		
Abbott AxSYM AUSAB	8					8	1		7	8			8		
Bio-Rad MONOLISA EIA	2					2			2	2			2		
DiaSorin ETI-AB-AUK Plus	8					8			8	8			8		
J&J Vitros	5					5			5	5			4	1	
Roche Elecsys	12					12			12	12			10		2
Siemens Advia	8					8			8	8				1	7
Siemens Immulite	11			1		10			11	11			11		
<b>Total Population</b>	<b>60</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>59</b>	<b>2</b>	<b>0</b>	<b>59</b>	<b>59</b>	<b>0</b>	<b>2</b>	<b>50</b>	<b>2</b>	<b>9</b>
<b>Flagging</b>		*****	*****	*****			*****	*****			*****	*****		*****	*****

**HBeAg**

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
DiaSorin ETI-EBK Plus			3			3			3				3		3
General Biologicals Co			1			1			1				1		1
<b>Total Population</b>	<b>0</b>	<b>0</b>	<b>4</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>4</b>	<b>4</b>	<b>0</b>	<b>0</b>
<b>Flagging</b>	*****	*****		*****	*****		*****	*****	*****	*****	*****	*****	*****	*****	*****

**HBsAg**

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
Abbott Architect			3			3			4			3			3
Abbott ImX/AxSYM			6			8			8			6			7
Bio-Rad EIA-Proc A			10			10			10			10			9
Bio-Rad MONOLISA Ultra			4			4			4			4			4
DiaSorin ETI-MAK-2 Plus			6			5			6			6			6
DiaSorin ETI-MAK-2 Proc A			4			4			4			4			4
J&J Vitros ECI			8			7			8			8			8
Roche Elecsys			10			13			13			10			13
Siemens Advia			10			11			11			10			11
Siemens Immulite			22			21			22			22			21
<b>Total Population</b>	<b>0</b>	<b>0</b>	<b>90</b>	<b>92</b>	<b>2</b>	<b>1</b>	<b>96</b>	<b>0</b>	<b>2</b>	<b>2</b>	<b>0</b>	<b>89</b>	<b>93</b>	<b>0</b>	<b>2</b>
<b>Flagging</b>	*****	*****		*****	*****		*****	*****	*****	*****	*****	*****	*****	*****	*****

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "\*\*\*\*\*" on the Flagging line of each specimen.